Shots:
- Partner Therapeutics has reported post-hoc analysis from the eNRGy study assessing zenocutuzumab (marketed as Bizengri in the US) in pts with advanced NRG1+ NSCLC
- In 27 pts with NRG1+ NSCLC treated with zenocutuzumab (≥3 doses) beyond radiographic progression, 81% had oligoprogression & 19% diffuse progression, extending median exposure to ~10 vs ~7mos. pre-progression.
- Additionally, 8 pts remained on therapy for >6mos. post-progression, incl. one for >23mos. & one for ~4yrs.; 22% continued zenocutuzumab after local management of progressing lesions. Results were presented at IASLC TTLC 2026
Ref: PRnewswire | Image: Partner | Press Release
Related News: Partner Therapeutics Reports CHMP’s Positive Opinion for Imreplys to Treat Exposure to Myelosuppressive Doses of Radiation
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
